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Since the identification of human immunodeficiency 
virus (HIV)-1 as the aetiological agent of acquired im-
mune deficiency syndrome (AIDS), several studies have 
associated different viral molecular characteristics, es-
pecially the diversity of the envelope gene, with disease 
progression (Potts et al. 1993, Santoro-Lopes et al. 2000). 
Most of these studies are focused on the envelope third 
variable region, or V3 loop, which is involved in HIV-1 
binding to the chemokine co-receptors 5 (R5) and/or CX-
CR4 (X4). This step is necessary for viral fusion to the 
host cell (Shioda et al. 1991). A change in viral tropism 
has been associated with different phases of HIV-1 infec-
tion, with a predominance of R5 tropic virus observed at 
the initial stages of infection. X4-tropic viruses emerge 
at advanced disease stages in about half of all cases and 
this emergence is correlated with clinical progression 
and CD4 T cell depletion (Richman & Bozzette 2004, 
Goetz et al. 2009). The pathogenic potential of X4 virus 
is highlighted by its capacity to induce syncytia forma-
tion (Richman & Bozzette 2004). Several bioinformat-
ics tools have been used to determine viral genotypic 
tropism, such as the website geno2pheno and the 11/25 
rule. Additionally, amino acid signatures at the V3 loop 
tip tetramer, which commonly harbour a proline at codon 
16 (15GPGR18), show a substitution to tryptophan (W) at 
this position in some Brazilian clade B envelopes and are 
referred to as B’ or Brazilian-B (Shioda et al. 1991, Potts 
et al. 1993, Pinto et al. 2008). The GWGR signature has 
a prevalence of 20-50% in Brazil and has been associ-
ated with a slower progression to AIDS (Santoro-Lopes 
et al. 2000, Casseb et al. 2002, 2004, de Brito et al. 2006). 
However, the actual relevance of this molecular diversity 
on treatment response is not yet clear. To expand the un-
derstanding of the potential role of genotypic viral tro-
pism, false-positive rate (FPR) values obtained at geno2-
pheno and the presence of the GWGR motif in patients on 
antiretrovirals (ARV), the correlations of these charac-
teristics with viral loads (VLs) and CD4+ T lymphocyte 
counts were assessed in patients during 48 weeks of first-
line highly active antiretroviral therapy (HAART).
PATIENTS, MATERIALS AND METHODS
Study population - HIV-1-infected individuals not 
exposed to antiretroviral therapy (ART), but with indi-
cations for treatment according to the Brazilian Clinical 
Guideline, were invited and those eligible were randomly 
assigned in a 1:1 ratio to receive either lopinavir or efa-
virenz with azithothymidine (AZT)/3TC backbone. Clini- 
cal follow-up was conducted at the HIV Clinic, Medicine 
School Hospital, Ribeirão Preto, São Paulo University to 
evaluate the virological and immunological responses of 
the patients to HAART during the 48 weeks of follow-
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While human immunodeficiency virus (HIV)-1 chemokine co-receptors 5 tropism and the GWGR motif in the 
envelope third variable region (V3 loop) have been associated with a slower disease progression, their influence on 
antiretroviral response remains unclear. The impact of baseline V3 characteristics on treatment response was evalu-
ated in a randomised, double blind, prospective cohort study with patients initiating highly active antiretroviral ther-
apy with lopinavir or efavirenz plus azithothymidine/3TC (1:1) over 48 weeks. Similar virological and immunological 
responses were observed for both treatment regimens. The 43 individuals had a mean baseline CD4 T cell count of 
119 cells/mm³ [standard deviation (SD) = 99] and a mean viral load of 5.09 log10 copies/mL (SD = 0.49). The GWGR 
motif was not associated with a CD4 T cell response, but predicted R5 tropism by the geno2pheno[clinical20%] algorithm 
correlated with higher CD4 T cell levels at all monitoring points (p < 0.05). Moreover, higher false-positive rates 
(FPR) values from this analysis revealed a strong correlation with CD4 T cell recovery (p < 0.0001). Transmitted 
drug resistance mutations, documented in 3/41 (7.3%) cases, were unrelated to the assigned antiretroviral regimen 
and had no impact on patient outcomes. In conclusion, naïve HIV-1 R5 infected patients exhibited higher CD4 T cell 
counts at baseline; this difference was sustained throughout therapy. The geno2pheno[clinical] option FPR positively 
correlated with CD4 T cell gain and may be useful in predicting CD4 T cell recovery.
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up. Data from patients who died before completing the 
follow-up were included in the baseline evaluation and 
the individuals who did not complete all visits were in-
cluded in an intention to treat (ITT) analysis. A written 
informed consent was obtained from all patients and 
both Institutional Review Boards approved the study.
Laboratory and molecular analysis - CD4 T cell 
counts and percentages (flow cytometry, BD, USA) and 
VLs (Branched DNA, Siemens, USA) were determined 
at baseline and at weeks 6, 12, 24, 36 and 48. CD4 T 
cell gain was calculated as the absolute cell count from 
each week of observation minus the baseline CD4 T cell 
count. HIV-1 RNA and genomic DNA were extracted 
using the QIAamp® RNA/DNA extraction kit (Qiagen, 
Germany) according to manufacturer instructions and 
were stored at -70ºC until used. Synthesis of comple-
mentary DNA (cDNA) was performed by reverse tran-
scription with Superscript III (Invitrogen, USA). Poly-
merase chain reaction amplification was performed 
on cDNA (pol) and proviral DNA (env) using a nested 
protocol as previously described (Ferreira et al. 2008). 
Amplicons were sequenced directly using BigDye and 
were resolved with an ABI 3100 Genetic Analyzer (Ap-
plied Biosystems, USA). Sequences of partial env and 
pol genes were manually edited with Sequencher 4.14 
(GeneCodes, USA) software. Multiple sequence align-
ments were performed using the CLUSTALW algorithm 
with a reference set obtained from the Los Alamos Se-
quence Database. HIV subtyping was screened using 
NCBI Genotyping and was confirmed by phylogenet-
ic methods using the software PAUP* version 4.0b10 
(Sinauer Associates, USA). Transmitted drug resistance 
mutations (tDRM) were defined according to Calibrat-
ed Population Resistance v.6 (HIV Stanford Database) 
and the International AIDS Society (IAS) 2010 muta-
tion list. Viral tropism was evaluated using the web-
site geno2pheno[co-receptor] bioinformatics tool (Sing et al. 
2007) and both clonal and clinical options were used to 
obtain FPR values. Cut-offs of 5.75% (MOTIVATE op-
tion) and 20% (Vanderkerckhove et al. 2011) were em-
ployed to predict X4 tropism using clonal and clinical 
data. To obtain the FPR using the clinical option, base-
line (absolute and percentage) CD4 T cells counts and 
VLs were added to the model. These predictions were 
analysed both as categorical variables (X4 or R5) and 
as continuous variables. V3 loop amino acid composi-
tion was determined by analysis of alignments with the 
HXB2 reference sequence from the Los Alamos Se-
quence Database (accession K03455).
Statistical analysis - Categorical variables were test-
ed using Fischer’s exact test or the Yates corrected test 
(two-tailed), as appropriate. Continuous variables were 
tested using the Mann-Whitney test, two-way analysis 
of variance (ANOVA) (non-parametric), the Spearman 
correlation and linear regression. Epinfo6 (Centers for 
Disease Control and Prevention) and GraphPad Prism 
5.0 software were used in the statistical analysis. Viro-
logical and CD4 T cell outcomes were evaluated as ITT, 
missing equals failure (ITT, M = F) and as treated (AT), 
missing equals exclusion (AT, M = E).
RESULTS
The 43 patients enrolled from 2004-2006 were most-
ly male (70%) and had a mean age of 41 years [standard 
deviation (SD) 15 years], a mean baseline CD4 T cell 
count of 119 cells/mm3 (SD = 99 cells/mm3) and a mean 
VL of 5.09 log10 c/mL (SD = 0.49). CD4 T cell counts 
and VLs are depicted in Table. Three patients died and 
two abandoned therapy before their first return at week 6 
of the follow-up. One patient discontinued treatment be-
fore 24 weeks and three left between 24-36 weeks of the 
follow-up. All three deaths occurred before concluding 
the clinical follow-up and these patients had baseline 
CD4 T lymphocyte counts below 50 cells/mm3.
Patients were randomly assigned in a 1:1 ratio to re-
ceive either lopinavir (48.8%) or efavirenz (51.2%) with 
AZT/3TC backbone. The tDRM frequency at baseline 
(available after treatment initiation) was 7.3%, all mu-
tations were observed in the protease gene (mutations 
V82L, I85V and G73S) and the predicted loss of ART 
susceptibility was not relevant to the assigned ARV 
regimen. V82L and I85V substitutions were observed in 
patients assigned to receive lopinavir; these individuals 
exhibited a similar response to those without detectable 
mutations. The G73S mutation was observed in a patient 
receiving efavirenz who died two weeks after enrolment 
without an evaluation of the ARV response. 
Virological and immunological outcomes after 
HAART on both regimen arms were comparable, with 
no differences between lopinavir and efavirenz response 
except for a higher occurrence of hypertriglyceridemia 
in the lopinavir group (data not shown). Viral suppres-
sion was achieved in most patients by week 24, when 
89% of individuals had viremia below detection limits. 
After 48 weeks of HAART, only two individuals (6%) 
had a detectable VL (> 50 copies/mL), with one on each 
regimen arm (AT, M = E). Further genotyping test anal-
ysis of one of these cases, RP16 on lopinavir + AZT/3TC 
therapy with several adherence issues, revealed the 
emergence of the mutation M184V, which is predicted to 
reduce 3TC susceptibility. 
V3 env region sequencing was performed for the 43 
patient samples, with 42 sequences validated; one se-
quence for each sample was obtained. All HIV-1 enve-
lopes were clade B, except for one subtype F that was 
excluded from the Brazilian-B GWGR analysis. HIV-1 
predicted tropism to CXCR4 co-receptor prevalence was 
17/42 (40%) when using geno2pheno[clonal20%], 24/42 (57%) 
when using geno2pheno[clinical20%] and 6/42 (14%) when us-
ing the MOTIVATE option (Table). Prediction of three 
sequences classified as X4 and 10 sequences classified 
as R5 by a clonal algorithm were discordant when clini-
cal data were incorporated into the algorithm. When se-
quences were classified by the V3 loop motif, 4/9 (44%) 
of GWGR, 4/12 (33%) of GPGR and 9/20 (45%) of “other 
motifs” were predicted to be X4 by geno2pheno[clonal20%]. 
Moreover, among “other motif” isolates, 6/20 had basic 
amino acids at positions 11 or 25 and 3/20 had a GWRR 
motif. No GPGR or GWGR isolate had basic amino acids 
at these positions. The six viruses harbouring basic ami- 
no acids at positions 11 and 25 had clonal and clinical FPR 
values below 20%, except for one sequence. This case had 
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a 30% FPR value when we used the clinical algorithm, 
despite presenting an arginine (R) at position 25. The V3 
loop alignment and tropism prediction using clonal data, 
clinical data and the 11/25 rule are shown in Fig. 1.
CD4 T cell counts at each interval were lower for pa-
tients with X4-tropic viruses and were significantly dif-
ferent when tropism was determined by geno2pheno[clinical 
20%] (Fig. 2A, B). CD4 T cell counts and VLs according 
to different tropism prediction criteria are described in 
Table. CD4 T lymphocyte cell counts throughout the 48 
weeks (Fig. 2C) and VLs (Fig. 2D) were comparable for 
patients infected with either GWGR or GPGR variants. 
Taking into consideration the FPR values gener-
ated using geno2pheno[clinica20%l] for each isolate from 
all cases (ITT analysis), the CD4 T cell gain showed a 
positive, significant correlation with FPR values at all 
observation weeks. This was observed by both linear 
regression (p < 0.0001) (Fig. 3) and the Spearman linear 
correlation (p < 0.01). A similar trend was also observed 
when only those completing week 48 of follow-up were 
evaluated (“as treated”, data not shown). Baseline CD4 
T cell counts and geno2pheno[clonal20%] FPR values were 
not significantly correlated with CD4 T cell gain (p 
= 0.3 and 0.2, respectively).
DISCUSSION
This study evaluated the potential role of the molecu-
lar characteristics of the HIV-1 envelope on CD4 T lym-
phocyte gains in patients initiating their first HAART 
regimen from a structured cohort study performed to 
compare two first-line regimens. Viral tropism was de-
termined by bioinformatics tools, using the geno2pheno 
algorithm with different criteria and inspecting the ami-
no acid composition of the V3 loop of env (11/25 rule). 
The geno2pheno clinical option incorporated VL, CD4 
T lymphocyte cell counts and percentages to generate an 
FPR value in which the predicted tropism was weighted 
by these parameters. Sequences were also evaluated us-
ing the MOTIVATE option, which is the most specific 
criterion for detection of X4-tropic viruses, as it uses a 
more stringent FPR cut-off. It is of note that both the MO-
TIVATE study and the European consensus recommend 
lower cut-offs of 5.75% and 10%, respectively, when only 
three or more sequences of each individual are available. 
Therefore, a cut-off of 20% was used for all analyses, 
as recommended by the European consensus for single 
sequences. The results exhibited some discordance in 
tropism interpretation when different algorithms were 
TABLE
CD4 T cell counts and viral load (VL) according to highly active antiretroviral therapy (HAART) 
allocation group, V3 motif and predicted viral tropism
n (%)
Baseline VL  
mean (SD)
Baseline CD4 T cell 
mean (SD)
CD4 T cells gain at 48 week 
mean (SD)
Randomization
Lopinavir + zidovudina /3TC 21 (49) 5.09 (0.12) 117 (22) 223 (22)
Efavirenz + zidovudina /3TC 22 (51) 5.09 (0.09) 122 (21) 212 (29)
V3 Motif
   GPGR 12 (29.3) 5.12 (0.12) 104 (23) 235 (43)
   GWGR 9 (21.9) 5.22 (0.17) 134 (34) 187 (38)
   Other 20 (48.8) 4.99 (0.12) 117 (24) 219 (23)
Tropism
   11/25 rule
      X4 6 (14.3) 4.98 (0.27) 99 (48) 180 (41)
      R5 36 (85.7) 5.11 (0.08) 125 (17) 223 (21)
   MOTIVATE (5.7%)
      X4 6 (14.3) 5.13 (0.19) 70 (31) 183 (53)
      R5 36 (85.7) 5.09 (0.08) 130 (17) 222 (20)
   geno2pheno[clonall20%]
      X4 17 (40.5) 5.07 (0.15) 90 (23) 187 (19)
      R5 25 (59.5) 5.11 (0.08) 142 (20) 237 (28)
   geno2pheno[clinical20%]
      X4 24 (57.1) 5.16 (0.11) 84 (20)a 192 (18)
      R5 18 (42.9) 5.00 (0.10) 170 (20)a 245 (34)
a: p < 0.01. CD4 T (cells/mm3) and VL (log10 copies/mL) values at baseline and CD4 T cells gain at the last monitoring point (week 
48) according to HAART group. Cases were pooled and described according to V3 loop motif and tropism prediction. Tropism 
was predicted using 11/25 rule and geno2pheno algorithm, considering a 20% cut-off as false-positive rate on clinical and clonal 
options and using MOTIVATE 5.75% clonal cut-off. SD: standard deviation.
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used. Interestingly, most patients had advanced disease 
at the beginning of treatment, with a mean CD4 T cell 
count of 119 cells/mm3; this could explain the tropism 
disparities when clinical data were incorporated.
To assess the impact of viral tropism on clinical evolu-
tion, both VL suppression and CD4 T cell recovery were 
followed-up for one year. Treatment, tDRM, V3 loop 
motif and viral tropism did not impact VL suppression. 
Lower numbers of CD4 T cells were observed at both the 
baseline and the follow-up weeks in patients infected with 
X4 virus using both clinical and clonal algorithms. Fur-
thermore, CD4 T cell numbers were significantly lower in 
patients harbouring X4 variants when prediction used the 
geno2pheno[clinical20%] option (Fig. 2A). The use of baseline 
CD4 T cell counts on the clinical algorithm could be re-
sponsible for this stronger association. However, baseline 
CD4 T cell counts did not show a correlation with CD4 
T cell gain (p = 0.3). Although CD4 T cell counts of R5-
infected patients remained higher at most determinations, 
CD4 T cell recovery was similar for both groups. In other 
words, despite the higher CD4 T cell counts in R5-infect-
ed patients, the response to HAART was comparable for 
both R5 and X4-infected individuals.
Values of FPR as continuous variables were also eval-
uated to assess its association to CD4 T cell gain. Using 
the geno2pheno[clinical] option, envelope sequences FPR 
values exhibited a strong correlation with CD4 T cell gain 
(p < 0.0001) (Fig. 3). Again, although CD4 T cell count is 
used in this model to determine geno2pheno[clinical] FPR, 
neither CD4 T cell baseline counts (p = 0.3) nor the clon-
al FPR (p = 0.2) per se revealed a significant correlation 
with CD4 T cell gain. This suggests that FPR generated 
by the geno2pheno clinical algorithm may constitute a 
potential predictor for CD4 T cell gain after therapy. The 
usefulness of this option has also been proposed in pre-
vious studies (Prosperi et al 2010).
 Neither the GWGR nor the GPGR V3 loop motif 
had an association with CD4 T cell gain, despite the 
fact that CD4 T cell numbers were slightly higher at 
baseline in the former group (Fig. 2C). An important 
Fig. 1: amino acid alignment of V3 loop. Selected positions represent codons 11/25 and V3 tip codons 15-18. Bold characters represent basic 
amino acids at positions 11 and 25 (left). First and second columns show false-positive rate (FPR) values obtained through geno2pheno clonal 
and clinical options. Third column represents tropism prediction according to rule 11/25 (right).
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prevalence of X4 variants in GWGR viruses was ob-
served using both the geno2pheno[clonal20%] (44%) and 
the geno2pheno[clinical20%] (67%) algorithms, contrary to 
previous studies, which suggested that GWGR viruses 
are rarely X4 (da Silva 2006, Leal et al. 2008). This 
difference could be due to the algorithm used, as most 
studies use the 11/25 rule as a prediction criterion. To 
clarify this matter, the presence of basic amino acids 
at positions 11 and 25 was evaluated in our sequences; 
none of the GWGR or GPGR isolates had basic amino 
acids at these codons. Interestingly, three V3 tip se-
quences of non-GWGR tryptophan-harbouring virus-
es, classified here as “other motifs”, were predicted as 
X4. These viruses had a G→R polymorphism in the V3 
loop tip at position 17 (15GWRR18), two had basic amino 
acids at codons 11 or 25 and one had a G→R substi-
tution at position 28, a highly conserved codon (Leal 
et al. 2008, Franca et al. 2011). GWRR seems to be a 
very rare motif previously documented in the state of 
Rio de Janeiro, Brazil and Paraguay and its biological 
relevance is yet to be understood (Cabello et al. 1995, 
Tanuri et al. 1999)
The small number of samples in this study limits the 
strength of these observations and it is conceivable that 
these outcomes may be different if a larger cohort was 
sampled and a longer follow-up period was employed. 
Further studies may provide support for the use of 
geno2pheno[clinical] analysis of V3 envelope sequences as 
a surrogate marker for CD4 T cell gain after ART.
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